Key result
GLP-1 RA use linked to higher risk of acute asthma exacerbations in adolescents with obesity.
Why the study?
Does glucagonlike peptide-1 receptor agonist use reduce acute asthma exacerbations in adolescents with overweight or obesity and asthma?
Does glucagonlike peptide-1 receptor agonist use reduce acute asthma exacerbations in adolescents with overweight or obesity and asthma?
GLP-1 RA use warrants caution in obese adolescents with asthma; this Level 3 association challenges expectations and leaves causality open.
This cohort study investigates the association between glucagonlike peptide-1 receptor agonist use and the risk of acute asthma exacerbations among adolescents with overweight or obesity and asthma.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question. Glucagonlike peptide-1 receptor agonist use was found to be associated with an increased risk of acute asthma exacerbations in adolescents with obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: